Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies.
The relationship of strength to muscle area was used to assess change in muscle quality after anabolic interventions. Study 1: asymptomatic human immunodeficiency virus-positive men (39 +/- 9 yr) were randomized to nandrolone (600 mg/wk) +/- resistance training (RT). Study 2: older healthy men (72 +/- 5 yr) were randomized to oxandrolone (20 mg/day) or placebo. Maximum voluntary strength was determined by the 1-repetition maximum (1-RM) method for leg press, flexion and extension, and cross-sectional area of leg muscles by MRI. From study week 0 to study week 12, muscle quality was unchanged with nandrolone, oxandrolone, or oxandrolone placebo, respectively, for total thigh muscles (1.23 +/- 0.012 vs. 1.27 +/- 0.29 kg/cm2; 9.0 +/- 1.1 vs. 8.9 +/- 1.2 N/cm2; 8.9 +/- 1.2 vs. 8.9 +/- 1.9 N/cm2) and hamstrings (0.41 +/- 0.08 vs. 0.43 +/- 0.07 kg/cm2; 0.90 +/- 0.14 vs. 0.95 +/- 0.016 N/cm2; 0.94 +/- 0.23 vs. 0.93 +/- 0.21 N/cm2). Lower-extremity 1-RM strength increased several times greater with RT+nandrolone (51-63% increases) than with nandrolone alone (4.7-16%), despite similar increases in muscle area; therefore, muscle quality increased from 1.13 +/- 0.17 to 1.51 +/- 0.18 kg/cm2 (+36 +/- 19%; P < 0.001) for total thigh muscle, 0.37 +/- 0.10 to 0.53 +/- 0.08 kg/cm2 (+49 +/- 39%; P < 0.001) for hamstrings, and 0.73 +/- 0.19 to 1.07 +/- 0.16 kg/cm2 (+55 +/- 36%; P < 0.001) for quadriceps. Thus androgen therapy alone did not improve muscle quality, but the addition of RT to nandrolone produced substantive improvements.
Schroeder
E Todd
ET
Division of Infectious Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA.
Terk
Michael
M
Sattler
Fred R
FR
D000368:Aged; D000369:Aged, 80 and over; D045930:Anabolic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000728:Androgens / Q000009:adverse effects / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects; D006679:HIV Seropositivity / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology*; D009277:Nandrolone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D009929:Organ Size / Q000187:drug effects; D010074:Oxandrolone / Q000009:adverse effects / Q000627:therapeutic use; D010809:Physical Fitness; D011446:Prospective Studies
D045930:Anabolic Agents; D000728:Androgens; D009277:Nandrolone; D010074:Oxandrolone; D000077603:Nandrolone Decanoate